|Title:||Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010||Authors:||YU-TSUNG HUANG
|Issue Date:||2014||Journal Volume:||58||Journal Issue:||7||Start page/Pages:||3814-3819||Source:||Antimicrobial Agents and Chemotherapy||Abstract:||
We used the Sensititre YeastOne (SYO) method (Trek Diagnostic Systems) to determine the MICs of nine antifungal agents against 474 nonduplicate blood Candida isolates. The MIC results were interpreted according to updated clinical breakpoints (CBPs) recommended by the Clinical and Laboratory Standards Institute (CLSI; document M27-S4) or epidemiology cutoff values (ECVs). The rates of fluconazole susceptibility were 99.2% (234/236) in Candida albicans, 86.7% (85/98) in C. tropicalis, and 97.7% (42/43) in C. parapsilosis. Among the 77 isolates of C. glabrata, 90.9% showed dose-dependent susceptibility (S-DD) to fluconazole. Nearly all isolates of C. albicans, C. parapsilosis, and C. krusei were susceptible to voriconazole; however, rates of voriconazole susceptibility were 78.6% in C. tropicalis. Few isolates of C. albicans (n = 5; 2.1%) and C. glabrata (n = 3; 3.9%), no isolates of C. parapsilosis, C. krusei, and C. guilliermondii, but 62.2% (n = 51) of C. tropicalis isolates were non-wild type for posaconazole susceptibility. For itraconazole susceptibility, 98.3% of C. albicans isolates were wild type, and 3.9% (n = 3) of C. glabrata isolates were non-wild type. Almost all of the isolates tested (>97% for all species) were susceptible to both micafungin and anidulafungin. All isolates tested were found to be wild type for amphotericin B susceptibility, with MICs of <1μg/ml. Further evaluation is needed to establish CBPs of antifungal agents by the 24-h SYO method for the management of patients with candidemia or other invasive candida infections. Copyright ? 2014, American Society for Microbiology. All Rights Reserved.
|URI:||https://scholars.lib.ntu.edu.tw/handle/123456789/561074||ISSN:||0066-4804||DOI:||10.1128/AAC.01035-13||SDG/Keyword:||amphotericin B; anidulafungin; antifungal agent; fluconazole; flucytosine; itraconazole; micafungin; posaconazole; voriconazole; antifungal agent; antifungal susceptibility; article; bloodstream infection; broth dilution; Candida; Candida albicans; Candida glabrata; Candida krusei; Candida parapsilosis; Candida tropicalis; candidemia; controlled study; dose response; human; incidence; major clinical study; minimum inhibitory concentration; nonhuman; Pichia guilliermondii; priority journal; Taiwan; blood; Candida; candidemia; cross infection; drug effects; hematologic disease; microbial sensitivity test; microbiology; Antifungal Agents; Candida; Candidemia; Cross Infection; Dose-Response Relationship, Drug; Hematologic Diseases; Humans; Microbial Sensitivity Tests; Taiwan
|Appears in Collections:||醫學院附設醫院 (臺大醫院)|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.